AU2017315273B2 - Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same - Google Patents

Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same Download PDF

Info

Publication number
AU2017315273B2
AU2017315273B2 AU2017315273A AU2017315273A AU2017315273B2 AU 2017315273 B2 AU2017315273 B2 AU 2017315273B2 AU 2017315273 A AU2017315273 A AU 2017315273A AU 2017315273 A AU2017315273 A AU 2017315273A AU 2017315273 B2 AU2017315273 B2 AU 2017315273B2
Authority
AU
Australia
Prior art keywords
day
fenfluramine
patient
syndrome
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315273A
Other languages
English (en)
Other versions
AU2017315273A1 (en
Inventor
Brooks Boyd
Stephen J. Farr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zogenix International Ltd
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017315273(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of AU2017315273A1 publication Critical patent/AU2017315273A1/en
Application granted granted Critical
Publication of AU2017315273B2 publication Critical patent/AU2017315273B2/en
Priority to AU2021204250A priority Critical patent/AU2021204250B2/en
Priority to AU2022279469A priority patent/AU2022279469B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2017315273A 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same Active AU2017315273B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021204250A AU2021204250B2 (en) 2016-08-24 2021-06-23 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
AU2022279469A AU2022279469B2 (en) 2016-08-24 2022-11-30 Formulation for inhibiting formation of 5-HT 2b agonists and methods of using same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US62/379,183 2016-08-24
US201762515383P 2017-06-05 2017-06-05
US62/515,383 2017-06-05
PCT/IB2017/054740 WO2018037306A1 (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021204250A Division AU2021204250B2 (en) 2016-08-24 2021-06-23 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same

Publications (2)

Publication Number Publication Date
AU2017315273A1 AU2017315273A1 (en) 2019-03-07
AU2017315273B2 true AU2017315273B2 (en) 2021-04-29

Family

ID=59955585

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017315273A Active AU2017315273B2 (en) 2016-08-24 2017-08-02 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
AU2021204250A Active AU2021204250B2 (en) 2016-08-24 2021-06-23 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
AU2022279469A Active AU2022279469B2 (en) 2016-08-24 2022-11-30 Formulation for inhibiting formation of 5-HT 2b agonists and methods of using same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021204250A Active AU2021204250B2 (en) 2016-08-24 2021-06-23 Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
AU2022279469A Active AU2022279469B2 (en) 2016-08-24 2022-11-30 Formulation for inhibiting formation of 5-HT 2b agonists and methods of using same

Country Status (15)

Country Link
US (6) US20180055789A1 (https=)
EP (2) EP4201427A1 (https=)
JP (3) JP2019526544A (https=)
KR (3) KR20230021172A (https=)
CN (2) CN109689103A (https=)
AU (3) AU2017315273B2 (https=)
CA (1) CA3032996C (https=)
ES (1) ES3029536T3 (https=)
IL (2) IL290727B2 (https=)
MX (2) MX2019001799A (https=)
RU (2) RU2746000C2 (https=)
SG (1) SG11201900975XA (https=)
TW (4) TW202432093A (https=)
WO (1) WO2018037306A1 (https=)
ZA (1) ZA201900766B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US11932001B2 (en) 2018-06-15 2024-03-19 Lg Chem, Ltd. Decoration member
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
EP3887481A4 (en) * 2018-11-30 2022-08-03 Zogenix International Limited METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
US20210137853A1 (en) 2019-09-17 2021-05-13 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CA3159112A1 (en) * 2019-11-21 2021-05-27 Shinkei Therapeutics, Inc. Cannabidiol and/or cobicistat combination drug therapy
TW202200152A (zh) 2020-04-30 2022-01-01 泰合生技藥品股份有限公司 氯巴占(clobazam)經皮傳遞系統及其用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230165810A1 (en) * 2021-12-01 2023-06-01 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025174742A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated Concomitant administration of miricorilant with cyp2c19 inhibitors
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177676A1 (en) * 2013-05-03 2014-11-06 Katholieke Universiteit Leuven Fenfluramine for use in the treatment of dravet syndrome
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (https=) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2663539B1 (fr) * 1990-06-22 1994-10-07 Adir Utilisation de la d-fenfluramine pour l'obtention de medicaments destines au traitement des deficiences immunitaires chez le sujet age.
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2685204B1 (fr) * 1991-12-19 1995-06-16 Palmer Research Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
EP0762877B1 (en) 1994-06-03 2001-03-21 THEJMDE Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7789039B2 (en) 2001-06-22 2010-09-07 Université Catholique de Louvain Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
AU2002324579B2 (en) 2001-07-31 2007-11-15 Wyeth Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
WO2006034465A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
EP1863381A4 (en) 2005-03-21 2009-09-09 Health Smart Ltd SYSTEM FOR CONTINUOUS BLOOD PRESSURE MONITORING
EP1888030A1 (en) 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP1937255A4 (en) 2005-09-14 2013-06-26 Univ Witwatersrand Jhb PHARMACEUTICAL COMPOSITION
WO2007034476A2 (en) 2005-09-19 2007-03-29 Biolert Ltd A device and method for detecting an epileptic event
JP2009517186A (ja) 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1971394A4 (en) 2005-12-28 2009-04-01 Neurovista Corp METHOD AND SYSTEMS FOR PROPOSING A TREATMENT FOR A PATIENT TO CHECK EPILEPSIA AND OTHER NEUROLOGICAL DISEASES
CN101365435A (zh) 2006-02-06 2009-02-11 诺瓦提斯公司 有机化合物的组合产品
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
JP2010501597A (ja) 2006-08-31 2010-01-21 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ 正のアロステリックａｍｐａ受容体モジュレーターを用いて呼吸抑制を阻害する方法
CA2662574A1 (en) * 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
EP2115540A4 (en) 2007-01-31 2011-02-02 Quintiles Transnat Corp Inc METHOD AND SYSTEMS FOR ASSIGNING REPRESENTATIVE ELEMENTS TO LOCATIONS IN CLINICAL ATTEMPTS
ES2599227T3 (es) 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
EP2125799A1 (en) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
US20120115958A1 (en) 2008-10-09 2012-05-10 Aziende Chim. Riun. Ang. Franc. A.C.R.A.F. S.P.A. Liquid pharmaceutical formulation containing paracetamol
CA2776945A1 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of Walter Reed Army Institute Of Research Methods and compositions for treating status epilepticus and seizures causing status epilepticus
TWI424832B (zh) 2008-12-15 2014-02-01 波提亞斯數位康健公司 與身體有關的接收器及其方法
WO2010104841A2 (en) 2009-03-09 2010-09-16 Celgene Corporation Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US20110212171A1 (en) 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011112606A1 (en) 2010-03-09 2011-09-15 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
AU2011283008A1 (en) * 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
AU2011322147A1 (en) 2010-10-26 2013-04-18 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US10183008B2 (en) * 2011-02-09 2019-01-22 University Of South Carolina Treatment of prolonged status epilepticus
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
WO2013096878A1 (en) 2011-12-22 2013-06-27 University Of Idaho Garcinia buchananii baker compounds, compositions and related methods
EP2806867A4 (en) 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
DE102012213040B4 (de) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder für physikalisch nicht klonbare Funktionen mittels Schwellendekodierung und entsprechendes Verfahren
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
WO2015013397A2 (en) 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
DK3035926T3 (da) 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015077057A1 (en) 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseases
JP6147676B2 (ja) * 2014-01-07 2017-06-14 東芝テック株式会社 情報処理装置、店舗システム及びプログラム
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
EP3136101B1 (en) 2014-04-22 2019-12-25 Tohoku University Method of testing for pulmonary hypertension
US10849518B2 (en) 2014-06-30 2020-12-01 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
CN107111673B (zh) 2014-09-29 2021-03-23 周格尼克斯国际有限公司 控制药物分配的控制系统
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2973140C (en) 2015-02-06 2025-09-16 Marinus Pharmaceuticals, Inc. Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
CN104800168A (zh) * 2015-04-08 2015-07-29 石家庄四药有限公司 司替戊醇干混悬剂及其制备方法
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
LT3505174T (lt) 2015-06-17 2020-09-10 The Trustees Of Columbia University In The City Of New York Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus
HK1245079A1 (zh) 2015-06-30 2018-08-24 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
KR102481631B1 (ko) 2015-08-24 2022-12-27 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
WO2017122701A1 (ja) 2016-01-14 2017-07-20 旭硝子株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
CN109069510A (zh) 2016-03-28 2018-12-21 武田药品工业株式会社 药物
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
EP4692048A3 (en) 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329
JP2020519594A (ja) 2017-05-09 2020-07-02 ゾゲニクス インターナショナル リミテッド フェンフルラミンを用いるドゥーゼ症候群の治療方法
US20190125697A1 (en) 2017-09-26 2019-05-02 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
CN112312929A (zh) 2018-04-18 2021-02-02 纽约市哥伦比亚大学理事会 用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
JP2021530541A (ja) 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
EP3887481A4 (en) 2018-11-30 2022-08-03 Zogenix International Limited METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
EP3930841A4 (en) 2019-02-25 2022-11-30 Zogenix International Limited FORMULATION TO IMPROVE SEIZURE CONTROL
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
WO2023034115A1 (en) 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177676A1 (en) * 2013-05-03 2014-11-06 Katholieke Universiteit Leuven Fenfluramine for use in the treatment of dravet syndrome
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUDIGOUDAR BASANAGOUD ET AL, "Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies", SEMINARS IN PEDIATRIC NEUROLOGY, SAUNDERS, PHILADELPHIA, PA, US, (2016-06-04), vol. 23, no. 2, doi:10.1016/J.SPEN.2016.06.003, pages 167 - 179 *

Also Published As

Publication number Publication date
JP2024180450A (ja) 2024-12-26
KR20230021172A (ko) 2023-02-13
TWI722233B (zh) 2021-03-21
AU2021204250A1 (en) 2021-07-22
RU2746000C2 (ru) 2021-04-05
TW202432093A (zh) 2024-08-16
RU2019105059A (ru) 2020-09-25
JP2019526544A (ja) 2019-09-19
US11040018B2 (en) 2021-06-22
US20210267916A1 (en) 2021-09-02
AU2022279469B2 (en) 2024-05-02
TW201821071A (zh) 2018-06-16
RU2019105059A3 (https=) 2020-11-25
AU2021204250B2 (en) 2022-09-01
US10603290B2 (en) 2020-03-31
RU2021106383A (ru) 2021-04-05
CN109689103A (zh) 2019-04-26
IL290727A (en) 2022-04-01
EP4201427A1 (en) 2023-06-28
US11759440B2 (en) 2023-09-19
EP3518975A1 (en) 2019-08-07
SG11201900975XA (en) 2019-03-28
ES3029536T3 (en) 2025-06-24
TWI776407B (zh) 2022-09-01
AU2017315273A1 (en) 2019-03-07
US11786487B2 (en) 2023-10-17
JP2022180461A (ja) 2022-12-06
KR20250040753A (ko) 2025-03-24
US20220125743A1 (en) 2022-04-28
AU2022279469A1 (en) 2023-02-02
CA3032996C (en) 2025-05-06
IL290727B1 (en) 2023-08-01
ZA201900766B (en) 2020-10-28
EP3518975B1 (en) 2025-04-09
US20190083424A1 (en) 2019-03-21
US20180055789A1 (en) 2018-03-01
CN120241681A (zh) 2025-07-04
US11406606B2 (en) 2022-08-09
TW202131908A (zh) 2021-09-01
KR20190040237A (ko) 2019-04-17
WO2018037306A1 (en) 2018-03-01
TW202308601A (zh) 2023-03-01
US20210393550A1 (en) 2021-12-23
IL264637B (en) 2022-04-01
MX2019001799A (es) 2019-06-13
US20200246281A1 (en) 2020-08-06
TWI907722B (zh) 2025-12-11
MX2023005140A (es) 2023-05-26
NZ750691A (en) 2021-06-25
IL290727B2 (en) 2023-12-01
CA3032996A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AU2022279469B2 (en) Formulation for inhibiting formation of 5-HT 2b agonists and methods of using same
US20190083425A1 (en) Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US8093296B2 (en) Methods for concomitant administration of colchicine and macrolide antibiotics
US7601758B1 (en) Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
NZ750691B2 (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
HK40012506A (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
HK40012506B (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
HK40007948A (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)